Table 2.
Scoring of regional TDP-43 pathology
| Case | Cell type | BA4 | Spinal cord | BA44/45 | BA46 | Cerebellum |
|---|---|---|---|---|---|---|
| 1 | Neuron | 2 | 2 | 1 | 1 | 0 |
| Glia | 0 | 0 | 0 | 0 | 0 | |
| 2 | Neuron | 2 | 3 | 1 | 1 | 0 |
| Glia | 3 | 3 | 1 | 1 | 0 | |
| 3 | Neuron | 1 | 2 | 0 | 1 | 0 |
| Glia | 2 | 2 | 0 | 0 | 0 | |
| 4 | Neuron | 3 | 3 | 1 | 1 | 0 |
| Glia | 3 | 3 | 1 | 1 | 0 | |
| 5 | Neuron | 1 | 1 | 1 | 1 | 0 |
| Glia | 2 | 2 | 1 | 2 | 0 | |
| 6 | Neuron | 2 | 2 | 1 | 1 | 0 |
| Glia | 2 | 2 | 1 | 1 | 0 |
The table summarizes pathological TDP-43 staining using a phospho-TDP-43 antibody. Scoring of TDP-43 pathology is based on the semi-quantitative scoring published previously (Gregory et al., 2019): 0—no evidence of TDP-43 pathology, 1—mild pathology, 2—moderate pathology and 3—severe pathology. Neuronal and glial pathology have been quantified individually.